The Impact of No-Call Rate in NIPT
An infographic that highlights the clinical importance of no-call rate in NIPT (non-invasive prenatal testing).
Articles and resources
Addressing evolving laboratory needs through innovative workflows
Revvity's Symposium presentation from ESHG 2023 (European Society of Human Genetics). A compilation of talks from forward-thinking laboratory leaders, highlighting their innovative methods and services.
Webinar: 1st trimester pre-eclampsia screening – From invention to implementation
In this webinar, the father of FMF pre-eclampsia prediction models, Professor Kypros Nicolaides provides his insights to current developments and future prospects in this field. As one remarkable milestone in the journey from invention to implementation of pre-eclampsia screening is the first recommendation in public health to offer preterm pre-eclampsia screening to all women in Ontario, Canada.
Revvity Tests Included in UK’s Updated NICE Diagnostic Guidance for Pre-Eclampsia DG-49
Two Revvity CE marked tests are recommended in latest version of NICE guidance “PLGF-based testing to help diagnose suspected preterm pre-eclampsia” for UK healthcare providers
Designing a quantitative PCR assay for fetal RhD genotyping from maternal plasma derived cell free fetal DNA (cffDNA)
M.Sc. Suvi Parviainen and Ph.D. Ville Veikkolainen. Poster presented at the ESHG conference 2022.
Consequences of imprecision in fetal fraction estimation on performance of cell-free DNA screening for Down syndrome
Persson F. and Cuckle H.S., Prenat Diagn. 2022
Rule-in and rule-out of pre-eclampsia using DELFIA Xpress PlGF 1-2-3 and sFlt-1: PlGF ratio
The objective of this study was to explore and validate thresholds for Placental growth factor (PlGF) and soluble fms-like tyrosine-kinase 1 (s-Flt-1) (as s-Flt-1: PlGF ratio), to rule-in and rule-out disease in women with suspected pre-eclampsia, using DELFIA® Xpress PlGF1-2-3 and sFlt-1 assays. Published in Pregnancy Hypertension, Volume 27, March 2022
Examination of False Positives in Fetal cfDNA Analysis
The lecture entitled “Clinical Validation of Fetal cfDNA Analysis Using Rolling-Circle-Replication and Imaging Technology in Osaka (CRITO Study) ” was presented by Dr Ritsuko Pooh at the 8th World Congress on Controversies in Preconception, Preimplantation and Prenatal Genetic Diagnosis (CoGEN) in 2021.
Implications of Fetal Fraction measurement variability in NIPS – Webinar & Transcript
The lecture entitled “Implications of fetal fraction measurement variability in NIPS” was presented by Dr Fredrik Persson at the 2021 International Society for Prenatal Diagnosis (ISPD) conference.
Clinical Validation of Fetal cfDNA Analysis Using Rolling-Circle-Replication and Imaging Technology in Osaka (CRITO Study)
Pooh, R.K.; Masuda, C.; Matsushika, R.; Machida, M.; Nakamura, T.; Takeda, M.; Ohashi, H.; Kumagai, M.; Uenishi, K.; Roos, F.; Persson, F.; Shimokawa, O. Clinical Validation of Fetal cfDNA Analysis Using Rolling-Circle-Replication and Imaging Technology in Osaka (CRITO Study). Diagnostics 2021, 11, 1837. https://doi.org/10.3390/diagnostics11101837
